Dual PDE 3/4 inhibition: A novel approach to airway disease?

The Lancet Respiratory Medicine

Volumn 1, Issue 9, 2013, Pages 669-670

  Wedzicha, Jadwiga A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; CYCLIC AMP; LIPOPOLYSACCHARIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; QVA 149; ROFLUMILAST; RPL 554; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHODILATING ACTIVITY; CARDIOVASCULAR DISEASE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG INDICATION; DRUG TOLERABILITY; DRUG TOLERANCE; ENZYME ACTIVITY; ENZYME INHIBITION; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART DISEASE; HUMAN; LETTER; LONG TERM CARE; MAINTENANCE THERAPY; NEBULIZER; NEUTROPHIL CHEMOTAXIS; PNEUMONIA; PRIORITY JOURNAL; REPEATED DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84887086305     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(13)70211-X     Document Type: Letter

References (9)

1. Powrie DJ, Wilkinson TMA, Donaldson GC, et al. Effect of tiotropium on inflammation and exacerbations in chronic obstructive pulmonary disease. Eur Resp J 2007, 30:472-478.
2. Wedzicha JA, Calverley PMA, Seemungal TA, Hagan G, Ansari Z, Stockley RA The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008, 177:19-26. for the INSPIRE Investigators.
3. Bardin PG, Dorward MA, Lampe FC, Franke B, Holgate ST Effect of selective phosphodiesterase 3 inhibition on the early and late asthmatic responses to inhaled allergen. Br J Clin Pharmacol 1998, 45:387-391.
4. Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007, 62:1081-1087.
5. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374:685-694.
6. Franciosi LG, Diamant Z, Banner KH, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med 2013, published online Oct 25. http://dx/doi.org/10.1016/S2213-2600(13)70187-5.
7. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013, 1:199-209.
8. Mannino DM, Thorn D, Swensen A, Holguin F Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008, 32:962-969.
9. Garcha D, Thurston S, Patel A, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 2012, 67:1075-1080.